Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q4 FY22 results · Jan–Mar 2022
Torrent Pharmaceuticals reported revenue from operations of ₹2,131.00 crore (up 10.0% from Q4 FY21) and net loss of ₹118.00 crore for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,131.00 | 1,937.00 | +10.0% | 2,108.00 | +1.1% |
| Other income | 56.00 | 39.00 | +43.6% | 48.00 | +16.7% |
| Total income | 2,187.00 | 1,976.00 | +10.7% | 2,156.00 | +1.4% |
| Profit before tax | (87.00) | 383.00 | Turned loss | 357.00 | Turned loss |
| Net profit for the period | (118.00) | 324.00 | Turned loss | 249.00 | Turned loss |
| EPS, basic (₹) | (6.98) | 19.16 | Turned loss | 14.75 | Turned loss |
| Net margin (%) | -5.5 | 16.7 | 11.8 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,662.00 | 1,468.00 | +13.2% | 1,588.00 | +4.7% |
| Other income | 61.00 | 91.00 | −33.0% | 37.00 | +64.9% |
| Total income | 1,723.00 | 1,559.00 | +10.5% | 1,625.00 | +6.0% |
| Profit before tax | 345.00 | 301.00 | +14.6% | 255.00 | +35.3% |
| Net profit for the period | 221.00 | 279.00 | −20.8% | 170.00 | +30.0% |
| EPS, basic (₹) | 13.08 | 16.48 | −20.6% | 10.06 | +30.0% |
| Net margin (%) | 13.3 | 19.0 | 10.7 |
Consolidated
- Filed with BSE
- 26 May 2022, 10:09 IST
- Board meeting
- 25 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 May 2022, 10:09 IST
- Board meeting
- 25 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE